



Use of fibrates/Omega 3 fatty acids is to reduce risk of pancreatitis and not to modify the CVD risk of the patient. Patients with triglyceride level of >5 mmol/L are at risk with levels >10 mmol/L at significantly higher risk of pancreatitis.

**Omega 3 and Atrial Fibrillation** – Jan 24 MHRA listed AF as common adverse drug reaction Patients should seek medical attention if they develop symptoms of AF whilst taking O3FA If patient develops AF whilst taking O3FA, then it should be permanently discontinued

**Caution:** combination of statin and fibrate increases the risk of myopathy.